Highlights Jun 22 - Jun 28, 2026
new every Sunday
This week brought a clearer picture of how psychedelics reorganize brain networks, alongside clinical questions about LSD, 5-MeO-DMT, and the role of therapy. A US military policy change also narrowed a longstanding federal barrier tied to prior psilocybin use.
-
01
An international brain imaging analysis finds psychedelics reorganize cortical connectivity, increasing global integration while reducing localized network segregation
Cross-compound imaging finds a shared shift toward more globally integrated and less locally segregated cortical communication.
-
02
LSD for depression shows mixed Phase 3 results as Definium's data highlights remission gains, weaker response rates, and unresolved comparisons with psilocybin
Phase 3 LSD data show stronger remission than response results, while highlighting the pitfalls of comparisons with psilocybin trials.
-
03
A new 5-MeO-DMT trial raises questions about how much psychotherapy adds to psychedelic-assisted treatment for depression and trauma-related symptoms
A 5-MeO-DMT trial asks whether minimal psychotherapy can sustain benefits, with major implications for cost and scalability.
-
04
The US military ended a 16-year drug testing ban on recruits with psilocybin use histories, signaling a narrower federal barrier for psychedelic-experienced applicants
The US military ended a 16-year recruiting barrier for applicants with prior psilocybin use, signaling a shift in federal drug policy.
-
05
Synethetic Ibogaine-Natural Tramadol
An investigation traces tramadol found in African plants to contamination, contrasting the case with ibogaine's traditional use in Gabon.
-
06
MDMA guide covering effects, dosage, safety, testing, contraindications, and practical harm reduction for people considering ecstasy use
A practical MDMA guide covers testing, dosing, contraindications, overheating, hydration, interactions, and safer-use planning.